. Author manuscript; available in PMC: 2023 Oct 31.

Published in final edited form as: J Thorac Cardiovasc Surg. 2022 Oct 8;165(3):828–839.e5. doi: 10.1016/j.jtcvs.2022.10.007

TABLE 2.

Pre- and post-atezolizumab pulmonary function tests^*

PFT factor	Pre-atezolizumab (mean values)	Post-atezolizumab (mean values)	Mean change (95% CI)
FEV1 (n = 150)	85.6%	84.3%	−1.3% (−3.1% to 0.5%)
FVC (n = 152)	93.0%	92.9%	−0.1% (−1.8% to 1.7%)
DLCO (n = 126)	79.2%	76.2%	−3.0% (−4.9% to −1.2%)

Results are shown as percent predicted. PFT, Pulmonary function test; CI, confidence interval; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusion capacity for carbon monoxide.

Patients with paired values at screening and surgery visits.